Madrid, February 3, 2015 – PharmaMar announces that the U.S. Food and Drug Administration (FDA) has granted priority review to YONDELIS® (trabectedin) New Drug Application (NDA) for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline. Janssen Research & Development, PharmaMar´s strategic partner for the development of YONDELIS® in the U.S., submitted the NDA on November 24, 20141.
↧